The stock price of Atricure Inc (NASDAQ: ATRC) has plunged by -3.04 when compared to previous closing price of 32.60, but the company has seen a -4.27% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-05-23 that MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure’s management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may acc.
Is It Worth Investing in Atricure Inc (NASDAQ: ATRC) Right Now?
The stock has a 36-month beta value of 1.60. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATRC is 47.71M, and at present, short sellers hold a 3.84% of that float. On June 19, 2025, the average trading volume of ATRC was 596.26K shares.
ATRC’s Market Performance
ATRC stock saw a decrease of -4.27% in the past week, with a monthly decline of -2.44% and a quarterly a decrease of -9.22%. The volatility ratio for the week is 2.49%, and the volatility levels for the last 30 days are 1.91% for Atricure Inc (ATRC). The simple moving average for the last 20 days is -5.57% for ATRC stock, with a simple moving average of -4.99% for the last 200 days.
Analysts’ Opinion of ATRC
Many brokerage firms have already submitted their reports for ATRC stocks, with JP Morgan repeating the rating for ATRC by listing it as a “Overweight.” The predicted price for ATRC in the upcoming period, according to JP Morgan is $40 based on the research report published on December 17, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see ATRC reach a price target of $32. The rating they have provided for ATRC stocks is “Outperform” according to the report published on April 23rd, 2024.
JMP Securities gave a rating of “Mkt Outperform” to ATRC, setting the target price at $60 in the report published on October 23rd of the previous year.
ATRC Trading at -2.75% from the 50-Day Moving Average
After a stumble in the market that brought ATRC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATRC starting from Doraiswamy Vinayak, who sale 2,500 shares at the price of $33.44 back on May 28 ’25. After this action, Doraiswamy Vinayak now owns 73,550 shares of Atricure Inc, valued at $83,600 using the latest closing price.
VINAYAK DORAISWAMY, the Officer of Atricure Inc, proposed sale 2,500 shares at $33.44 during a trade that took place back on May 28 ’25, which means that VINAYAK DORAISWAMY is holding shares at $83,600 based on the most recent closing price.
Stock Fundamentals for ATRC
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.75 for the gross margin
The net margin for Atricure Inc stands at -0.08. The total capital return value is set at -0.07. Equity return is now at value -8.38, with -6.45 for asset returns.
Based on Atricure Inc (ATRC), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -7.41.
Currently, EBITDA for the company is -18.53 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of 3.21. The receivables turnover for the company is 7.58for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
To sum up, Atricure Inc (ATRC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
